Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

•HFrEF is a debilitating disease with substantial morbidity, mortality, and costs.•SGLT2i reduce adverse cardiovascular (including HF) and renal events.•SGLT2i have ushered in a new treatment paradigm for HFrEF management.•Collaboration between preventive cardiology and heart failure will optimize HF care.•Collaboration aims to optimize CV risk factors and SGLT2i access and adherence.